3.7216 +0.02 (0.58%)
After hours: 4:11PM EDT
|Bid||3.6000 x 1100|
|Ask||3.7300 x 800|
|Day's Range||3.6700 - 3.7800|
|52 Week Range||2.2500 - 3.8200|
|Beta (3Y Monthly)||0.45|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 7, 2019 - May 13, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.00|
PDL BioPharma's (PDLI) earnings exceed estimates in Q4. Lower royalties as well as weak product sales induce a downfall in year-over-year revenues.
The Incline Village, Nevada-based company said it had net income of 11 cents per share. Earnings, adjusted for one-time gains and costs, came to 10 cents per share. The biotechnology company posted revenue ...
INCLINE VILLAGE, Nev. , March 14, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) reports financial results for the three and 12 months ended December ...
INCLINE VILLAGE, Nev. , March 12, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that Peter Garcia , PDL's vice president and chief financial ...
INCLINE VILLAGE, Nev., March 7, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (PDLI) today announced that it will release its 2018 fourth quarter and full year financial results for the period ended December 31, 2018, on Thursday, March 14, 2019, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m., Eastern time, to discuss the operating and financial results and recent developments. A slide presentation relating to the call will be available via the webcast link on the PDL website at http://www.pdl.com.
INCLINE VILLAGE, Nev. , March 5, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that Dominique Monnet , PDL's president and chief executive ...
INCLINE VILLAGE, Nev., March 4, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL", NASDAQ: PDLI) announces the U.S. commercial launch of an authorized generic of Tekturna®, aliskiren hemifumarate 150 mg and 300 mg tablets. The authorized generic has the same drug formulation as Tekturna. Noden will continue to manufacture and commercialize prescription aliskiren products under the Tekturna and Tekturna HCT® (aliskiren and hydrochlorothiazide) brands in the United States, and the Rasilez® and Rasilez HCT® brands in international markets (collectively, the "Tekturna Products"). The authorized generic launch does not include Tekturna HCT.
[Editor's note: This story was previously published in May 2018. It has since been updated and republished.] Do you think penny stocks are best left to amateur traders who don't understand that cheap stocks are cheap for a reason? It's not an entirely unfair assessment. Many of these young (and doomed companies) are the beneficiaries of great sales pitches, but their investors often end up suffering buyer's remorse.It's a misnomer, however, to think all penny stocks -- let's quantify them as equities priced at less than $5 per share -- aren't worth owning. Thanks to factors ranging from prolonged weakness in the commodities market to strategic stock splits to poorly-timed IPOs, a handful of these low-priced equities are actually compelling prospects. * 7 Cheap Stocks That Make the Grade In fact, here's a run-down of four of the best penny stocks to mull for 2018, and maybe beyond, none of which aren't exchange-listed names.InvestorPlace - Stock Market News, Stock Advice & Trading TipsSource: Irene Grassi via Wikimedia (Modified) AK Steel Holding Corporation (AKS)One would think the steel business to be a steady and predictable one, with these stocks (and steel prices) ebbing and flowing more or less with the bigger economic cycle. One would be wrong in thinking this, however.The steel industry is a volatile mess, with ever-changing supply and demand making it impossible for the likes of AK Steel Holding Corporation (NYSE:AKS) to commit to a plan for the future.The end result? An already-cheap AKS stock has basically gone nowhere for the past 15 years, with everything that could go wrong during that time going wrong at an inopportune time.That may finally be on the verge of changing, however. With President Trump at least willing to try to level the playing field between the United States' steel companies and overseas rivals at the same time the global economy appears to be picking up some steam, AK Steel is in a proverbial sweet spot.Analysts think so anyway, with earnings and revenue projected to grow this year.Source: Shutterstock PDL BioPharma Inc (PDLI)PDL BioPharma (NASDAQ:PDLI) is a curious beast. It was initially established as a vehicle to acquire the rights to, or patents on, highly marketable drugs that would ultimately drive income for its investors.It worked too, for a while. As time marched on, however, drug developers realized they could do for themselves what PDL was doing. Ergo, PDL BioPharma has been struggling for a while now to acquire drugs and marketing rights at prices that left room for healthy dividends.That's a big part of the reason PDLI stock has fallen from a value of more than $30 in 2006 to a price of only $3.70 per share now. * 7 Healthy Dividend Stocks to Buy for Extra Stability The bears may have overshot with their pessimism though. PDL BioPharma could arguably overpay for a drug and still be money ahead.Source: Shutterstock Groupon Inc (GRPN)Talk about a fall from grace! Yes, Groupon (NASDAQ:GRPN) was a marker darling when it went public back in 2011, at a price of $28 per share. It has a honeymoon that didn't last long at all though, with shares retreating into penny stock territory less than a year later where it's been stuck ever since.And truth be told, Groupon shares deserved the beating they took. Not only was its pre-IPO growth rate not built to last, a host of competition has stepped up to the plate in the meantime. Net income peaked in 2012, and sales peaked in 2015.The daily-deals company may have finally found a winning formula though, setting the stage for a better 2019 and beyond.Analysts say that while sales are apt to fall another 8.2% this year, income is projected to improve. That may be all traders need to see to get this stock back in a nice uptrend.Source: Brownpau via Flickr (Modified) Zynga Inc (ZNGA)Last but not least, put Zynga (NASDAQ:ZNGA) on your list of penny stocks to mull for 2019. Yes, this is the same Zynga behind great online games like Words With Friends, FarmVille and several other titles you may not have realized were part of its library.This is the same Zynga that Facebook dropped an exclusivity arrangement with back in 2012, undermining its well-received IPO from 2011 and sending the stock to a sub-$5 price where it's been (almost) ever since. Though Zynga hasn't done poorly, it's certainly not done nearly as well as investors were expecting it too when it first IPO'd. * 9 High-Growth Stocks to Buy Now for Monster Returns Change is brewing though. Last year CEO and founder Mark Pincus gave up his control of the company by scrapping the two classes of voting shares that granted him an inordinate degree of voting power.That's not to say he alone was the reason the company was unable to grow in a meaningful way, but it certainly didn't help. In the meantime, that news comes at a time when revenue and income are starting to edge higher anyway.Not too many investors have noticed yet, but when they do, ZNGA is apt to get over the $5 hump. A more equitable voting rights scheme will only bolster the bullish case.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can follow him on Twitter, at @jbrumley.Compare Brokers The post 4 Penny Stocks to Own for 2019 appeared first on InvestorPlace.
Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in October due to various reasons. Nevertheless, the data show elite investors’ consensus picks have done well on average over the long-term. The top 30 S&P 500 stocks among hedge funds at […]
PDL BioPharma (PDLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NEW YORK, Nov. 30, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
With Thanksgiving behind us here's a few biotech/ healthcare companies that might be worth looking at before after your meal HENDERSON, NV / ACCESSWIRE / November 26, 2018 / Today we are highlighting: ...
INCLINE VILLAGE, Nev. , Nov. 19, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that management will present at the Piper Jaffray Healthcare ...
PDL BioPharma's (PDLI) earnings trump estimates in Q3. Higher royalties and product sales aid a significant surge in year-over-year revenues.
/ Healthcare stocks are rallying after Tuesday's US midterm elections. According to Modern Healthcare* the healthcare industry will continue to drive the nation's employment growth through 2026 by adding around 4 million new jobs, accounting for about a third of total job growth, according to Bureau of Labor Statistics data. Modern Healthcare cites that ''the healthcare industry has long fueled the country's economy.
On a per-share basis, the Incline Village, Nevada-based company said it had profit of 18 cents. Earnings, adjusted for one-time gains and costs, were 9 cents per share. The biotechnology company posted ...
Announces CEO succession plan INCLINE VILLAGE, Nev. , Nov. 6, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) reports financial results for the three ...
INCLINE VILLAGE, Nev., Oct. 31, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (PDLI) today announced that it will release its third quarter financial results for the period ended September 30, 2018, on Tuesday, November 6, 2018, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m., Eastern time, to discuss the operating and financial results and recent developments. A slide presentation relating to the call will be available via the webcast link on the PDL website at http://www.pdl.com. To access the live and subsequently archived webcast of the conference call, go to the Company's website and go to "Events & Presentations." Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.
INCLINE VILLAGE, Nev. , Oct. 8, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL") (NASDAQ: PDLI) announces the appointment of Edward Imbrogno as Vice President of Finance, a new position. Mr. ...
INCLINE VILLAGE, Nev. , Sept. 26, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that John McLaughlin , PDL's chief executive officer, will ...